Clin Cancer Res:癌症干细胞和巨噬细胞互作能够促使前列腺癌恶化和增强雄激素阻断治疗抗性

2018-05-06 AlexYang MedSci原创

癌症干细胞(CSCs)能够导致前列腺癌的恶化和雄激素阻断治疗(ADT)抗性的增强。由于CSCs依赖于它们特异的微环境,包括肿瘤相关的巨噬细胞(TAMs),阐释CSCs和TAMs之间的互作网络也许能够更加有效的抑制前列腺癌的恶化和对ADT的抗性。研究人员利用RNA-seq、co-IP和其他的试验评估了维持CSCs干细胞特性的细胞内机制,还利用共培养系统和细胞激素抗体试验来检测CSCs和TAMs之间的

癌症干细胞(CSCs)能够导致前列腺癌的恶化和雄激素阻断治疗(ADT)抗性的增强。由于CSCs依赖于它们特异的微环境,包括肿瘤相关的巨噬细胞(TAMs),阐释CSCs和TAMs之间的互作网络也许能够更加有效的抑制前列腺癌的恶化和对ADT的抗性。

研究人员利用RNA-seq、co-IP和其他的试验评估了维持CSCs干细胞特性的细胞内机制,还利用共培养系统和细胞激素抗体试验来检测CSCs和TAMs之间的内在联系,并且建立了一个正位的前列腺癌模型来评估CSCs与TAMs互作,在体内对ADT抗性的影响。研究发现,自噬相关基因7(ATG7)能够通过β-连环蛋白结合在OCT4启动子上,来促进OCT4的转录,进一步促成了前列腺癌中CSC的特性,包括自我更新、肿瘤起始和药物抗性。另外,CSCs能够通过促使单核细胞/巨噬细胞成为TMAs来重建其特异性的微环境,并且CSC促成的TMAs反过来能够通过白介素-6(IL6)/STAT3来促进CSCs的干细胞特性,以及前列腺癌的恶化和ADT抗性。更进一步的是,以CSCs和TAMs互作为靶标,通过抑制ATG7/OCT4和IL6受体,在正位前列腺癌模型中能够有效的减弱ADT抗性。

最后,研究人员指出,以CSCs和它们的微环境为靶标比单独以CSCs为靶标更为有效,也为前列腺癌中减弱ADT的抗性提供了一个可行的方法。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-05-24 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-12-26 yige2012
  4. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-05-08 ylz8405
  7. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-05-07 kafei

    学习学习谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-05-07 122a588dm47暂无昵称

    学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1710135, encodeId=a06e1e1013532, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu May 24 12:54:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641270, encodeId=64aa16412e025, content=<a href='/topic/show?id=469998e01fb' target=_blank style='color:#2F92EE;'>#雄激素阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98701, encryptionId=469998e01fb, topicName=雄激素阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62c22776697, createdName=ms5106640509429053, createdTime=Sat Sep 22 22:54:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665952, encodeId=a0ad166595268, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Dec 26 22:54:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333008, encodeId=5c8d1333008f7, content=<a href='/topic/show?id=2ab5e13481f' target=_blank style='color:#2F92EE;'>#癌症干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71348, encryptionId=2ab5e13481f, topicName=癌症干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385155, encodeId=cbdb1385155ad, content=<a href='/topic/show?id=fd1798e0222' target=_blank style='color:#2F92EE;'>#雄激素阻断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98702, encryptionId=fd1798e0222, topicName=雄激素阻断治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471584, encodeId=ab3714e1584ab, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 08 11:54:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312796, encodeId=4330312e96a7, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon May 07 07:41:24 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312680, encodeId=acdc31268045, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=883d2348002, createdName=122a588dm47暂无昵称, createdTime=Mon May 07 01:04:08 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312622, encodeId=0be731262294, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun May 06 21:32:07 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-05-06 虈亣靌

    谢谢分享谢谢分享

    0

相关资讯

Eur J Cancer:卡巴他赛在激发试验在重度治疗转移难治性前列腺癌患者中的疗效分析

之前的转移性去势难治性前列腺癌(mCRPC)治疗选择多烯紫杉醇(DOC)、卡巴他赛(CABA)和新激素治疗(NHT)。因此,治疗选择有限。DOC的再激发由于毒性的积累,使用也是受限的。最近,有研究人员调查了CABA再激发在mCRPC中治疗的活性和安全性。研究总共包括了562名患者,其中69名患者接受了CABA再激发(25 mg/m2 q3w, 58%; 20 mg/m2 q3w, 27.5%; 其

CLIN CANCER RES:STAT5A/B阻滞使前列腺癌对放疗敏感

器官局限性前列腺癌的标准治疗措施是手术或放疗,局部晚期前列腺癌通常只进行放疗或联合去势治疗。CLIN CANCER RES近期发表了一篇文章,研究Stat5a/b是否参与前列腺癌双链DNA断裂修复以及Stat5阻滞是否可以使前列腺癌对放疗敏感。

BJU Int:去势难治性前列腺癌(CRPC)患者中,间断性多烯紫杉醇治疗与持续性多烯紫杉醇治疗比较

最近,有研究人员在转移性趋势难治性(mCRPC)患者中调查了间断性间断性多烯紫杉醇治疗与持续性多烯紫杉醇治疗的优劣。研究包括了187名化疗的mCRPC患者,这些患者分配到两个不同的小组中:间断性多烯紫杉醇和持续性多烯紫杉醇。在两个小组中,多烯紫杉醇使用量为每周35mg/m2或者每3周75mg/m2。初级结果为一年生存率,次级结果为总生存、无进展自由生存(PFS)、治疗失败中位时间(TTF)和毒性。

Sci Rep:STEAP2敲除能够减少前列腺癌细胞的入侵能力

与正常前列腺比较,前列腺-2的六次跨膜上皮抗原(STEAP2)表达在前列腺癌中增加,表明了STEAP2也许能够促进前列腺癌的恶化。最近,有研究人员进行了旨在阐明STEAP2在前列腺致瘤过程中的功能作用情况和评估将其敲除后是否能够减少前列腺癌细胞侵入能力的研究。研究人员将STEAP2 siRNA转化进入PC3和LNCaP细胞系中,并且分析了增殖、迁移、入侵和基因表达情况。研究人员根据格林森得分情况,

Nat Commun:前馈α粒子放射治疗能够根治雄激素受体依赖的前列腺癌

人类激肽释放酶肽酶2(hk2)是一种前列腺特异性酶,它的表达受雄激素受体(AR)控制。AR是前列腺癌(PCa)的核心致瘤驱使因子,并且在癌症的DNA修复过程是是关键的调控因子。最近,有研究人员报道了一个创新的治疗策略,该策略利用了激素-DNA修复回路来促使分子特异性的α粒子在PCa中的注入。前列腺癌α粒子注入是通过分子特异性靶标位点和针对hK2的人源化单克隆抗体hu11B6的内化来引起的,并且进一

Nat Commun:多方面的免疫调控和组织向性临床细菌分离能够促进前列腺癌免疫治疗

免疫检查点抑制剂对一些免疫反应迟钝的肿瘤并不十分有效,比如前列腺癌,且前列腺癌还包括了罕见的肿瘤浸润淋巴细胞现象。最近,有研究人员假设选择组织特异性和免疫调控细菌能够促进这些免疫治疗的效果。研究人员在研究中展示了一个来源于病人的前列腺特异性细菌,CP1,结合抗PD-1免疫治疗方法,能够在正位的MYC-和PTEN突变的前列腺癌模型中增加生存且减少肿瘤负担。CP1在尿道内特异性定殖并且能够在肿瘤上增殖